Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Moving from stadardized to individualized dosing for targeted therapies

Joseph Ciccolini • 11 Sep 2022
ESMO 2022
General

Joseph Ciccolini, PharmD, PhD, Aix Marseille University & La Timone University Hospital of Marseille, Marseille, France, discusses the current state and future directions of individualizing targeted therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Joseph Ciccolini

0:32
Highlights in pharmacy at ESMO 2022
Joseph Ciccolini • 12 Sep 2022
1:02
The impact of renal impairment on uracil levels and the rate of false-positives in DPD testing
Joseph Ciccolini • 11 Sep 2022
0:55
Dose individualization of TKIs
Joseph Ciccolini • 11 Sep 2022

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals